Navigation Links
Inflammation contributes to colon cancer
Date:1/21/2009

Researchers led by Drs. Lillian Maggio-Price and Brian Iritani at The University of Washington found that mice that lack the immune inhibitory molecule Smad3 are acutely sensitive to both bacterially-induced inflammation and cancer. They report these findings in the January 2009 issue of The American Journal of Pathology.

Bacteria contribute to the development of certain cancers, in some measure, by stimulating chronic inflammation. Absence of a molecule that inhibits inflammation, Smad3, may therefore increase susceptibility to colon cancer.

To examine whether Smad3 signaling contributes to development of colon cancer, Maggio-Price et al examined mice deficient in Smad3 that lack of adaptive immune responses. They found that these mice are acutely sensitive to bacterially-induced inflammation and cancer due to both deficient T regulatory cell function and increased expression of proinflammatory cytokines. Through increased expression of both pro-oncogenic and anti-apoptotic proteins, epithelial cells in colonic tissues underwent both enhanced proliferation and survival.

"That the inflammatory response to microorganisms is a key event in these results reveals important 'tumor-suppressive' functions for Smad3 in T effector cells, T regulatory cells, and intestinal epithelial cells, all of which may normally limit the development of colon cancer in response to bacterial inflammation," explains the groups led by Dr. Maggio-Price and Dr. Iritani.


'/>"/>

Contact: Angela Colmone
acolmone@asip.org
301-634-7953
American Journal of Pathology
Source:Eurekalert

Page: 1

Related medicine news :

1. Control of Inflammation May Benefit Many of the Most Feared Illnesses in Middle and Old Age
2. Inflammation Markers May Help Predict Stroke Risk
3. Lung cancer cells activate inflammation to induce metastasis
4. Inflammation: Connecting the Mouth and Body?
5. Pelvic Inflammation Puts Girls at Risk for Repeat STIs
6. The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease
7. Researchers describe how chronic inflammation can lead to stomach cancer
8. Latest Pistachio Study Reveals Significant Reduction in Markers of Inflammation - an Emerging Risk Factor in Heart Disease
9. Fatness Boosts Inflammation in Body
10. Simple, inexpensive and objective tools for the assessment of mucosal inflammation: fecal markers
11. Loss of sleep, even for a single night, increases inflammation in the body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are ... saves lives. However, if one isn’t accessible in certain locations, the risk of ... I came up with this idea," said an inventor from Ridgecrest, Calif. , ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, ... Educational Leadership and Administration at St. Thomas University in Miami, Florida, was selected ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... emergency rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. ... said Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It ...
(Date:9/22/2017)... Diego, CA (PRWEB) , ... September 22, 2017 ... ... offer groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, ... Smart Mart has stated to offer wearable, and customers can find clothing at ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , ... wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Sept. 5, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral ... concluded its meeting with the U.S. Food and Drug ... formulation. At the ... pathway for submission of ORMD-0801, would be a Biologics ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology: